A citation-based method for searching scientific literature

Mark Lebwohl, Andrew Blauvelt, Carle Paul, Howard Sofen, Jolanta Węgłowska, Vincent Piguet, Daniel Burge, Robert Rolleri, Janice Drew, Luke Peterson, Matthias Augustin. J Am Acad Dermatol 2018
Times Cited: 70







List of co-cited articles
863 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Linda Stein Gold, Jerry Bagel, Mark Lebwohl, J Mark Jackson, Rongdean Chen, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin. J Drugs Dermatol 2018
24
20

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.
Zarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, Lesley S Exton, M Firouz Mohd Mustapa, Eleanor Samarasekera, A David Burden, Ruth Murphy, Caroline M Owen, Richard Parslew,[...]. J Invest Dermatol 2017
83
7

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
Boni E Elewski, Lluís Puig, Margaret Mordin, Isabelle Gilloteau, Bintu Sherif, Todd Fox, Ari Gnanasakthy, Charis Papavassilis, Bruce E Strober. J Dermatolog Treat 2017
29
17

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.
C H Smith, Z K Jabbar-Lopez, Z Z Yiu, T Bale, A D Burden, L C Coates, M Cruickshank, T Hadoke, E MacMahon, R Murphy,[...]. Br J Dermatol 2017
142
7

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
K Reich, M Gooderham, A Bewley, L Green, J Soung, R Petric, J Marcsisin, J Cirulli, R Chen, V Piguet. J Eur Acad Dermatol Venereol 2018
33
15

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Kim Papp, Kenneth Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab G Girgis, Sudeep Kundu, Subhashis Banerjee. N Engl J Med 2018
156
7

Psoriasis.
Jacqueline E Greb, Ari M Goldminz, James T Elder, Mark G Lebwohl, Dafna D Gladman, Jashin J Wu, Nehal N Mehta, Andrew Y Finlay, Alice B Gottlieb. Nat Rev Dis Primers 2016
324
7

Definition of treatment goals for moderate to severe psoriasis: a European consensus.
U Mrowietz, K Kragballe, K Reich, P Spuls, C E M Griffiths, A Nast, J Franke, C Antoniou, P Arenberger, F Balieva,[...]. Arch Dermatol Res 2011
490
7

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.
Phyllis I Spuls, Lidian L A Lecluse, Marie-Louise N F Poulsen, Jan D Bos, Robert S Stern, Tamar Nijsten. J Invest Dermatol 2010
151
7


Clinical improvement in psoriasis with specific targeting of interleukin-23.
Tamara Kopp, Elisabeth Riedl, Christine Bangert, Edward P Bowman, Elli Greisenegger, Ann Horowitz, Harald Kittler, Wendy M Blumenschein, Terrill K McClanahan, Thomas Marbury,[...]. Nature 2015
150
7

Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Mamitaro Ohtsuki, Akimichi Morita, Masatoshi Abe, Hidetoshi Takahashi, Noriko Seko, Alexander Karpov, Tomohiro Shima, Charis Papavassilis, Hidemi Nakagawa. J Dermatol 2014
64
7


An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Mark Lebwohl, Enno Christophers, Richard Langley, Jean P Ortonne, Janet Roberts, Christopher E M Griffiths. Arch Dermatol 2003
271
7


Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis.
Yan Zheng, Dimitry M Danilenko, Patricia Valdez, Ian Kasman, Jeffrey Eastham-Anderson, Jianfeng Wu, Wenjun Ouyang. Nature 2007
7

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
P Rich, B Sigurgeirsson, D Thaci, J-P Ortonne, C Paul, R E Schopf, A Morita, K Roseau, E Harfst, A Guettner,[...]. Br J Dermatol 2013
185
7

Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Elizabeth G Araujo, Matthias Englbrecht, Sabrina Hoepken, Stephanie Finzel, Eleni Kampylafka, Arnd Kleyer, Sarah Bayat, Verena Schoenau, Axel Hueber, Juergen Rech,[...]. Semin Arthritis Rheum 2019
58
8

Development, cytokine profile and function of human interleukin 17-producing helper T cells.
Nicholas J Wilson, Katia Boniface, Jason R Chan, Brent S McKenzie, Wendy M Blumenschein, Jeanine D Mattson, Beth Basham, Kathleen Smith, Taiying Chen, Franck Morel,[...]. Nat Immunol 2007
7

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study.
Robert Bissonnette, François Harel, James G Krueger, Marie-Claude Guertin, Malorie Chabot-Blanchet, Juana Gonzalez, Catherine Maari, Isabelle Delorme, Charles W Lynde, Jean-Claude Tardif. J Invest Dermatol 2017
53
9

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
Kim A Papp, Yves Poulin, Robert Bissonnette, Marc Bourcier, Darryl Toth, Leslie Rosoph, Melanie Poulin-Costello, Mike Setterfield, Jerry Syrotuik. J Am Acad Dermatol 2012
58
8

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Howard Sofen, Stacy Smith, Robert T Matheson, Craig L Leonardi, Cesar Calderon, Carrie Brodmerkel, Katherine Li, Kim Campbell, Stanley J Marciniak, Yasmine Wasfi,[...]. J Allergy Clin Immunol 2014
190
7

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
A Nast, P Gisondi, A D Ormerod, P Saiag, C Smith, P I Spuls, P Arenberger, H Bachelez, J Barker, E Dauden,[...]. J Eur Acad Dermatol Venereol 2015
269
7

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
Jeffrey R Curtis, Xavier Mariette, Cécile Gaujoux-Viala, Andrew Blauvelt, Tore K Kvien, William J Sandborn, Kevin Winthrop, Marc de Longueville, Ivo Huybrechts, Vivian P Bykerk. RMD Open 2019
23
21

Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren. PLoS One 2019
67
7

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.
April W Armstrong, Keith A Betts, James E Signorovitch, Murali Sundaram, Junlong Li, Arijit X Ganguli, Eric Q Wu. Curr Med Res Opin 2018
18
27

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Sivem Afach, Liz Doney, Corinna Dressler, Camille Hua, Canelle Mazaud, Céline Phan, Carolyn Hughes, Dru Riddle,[...]. Cochrane Database Syst Rev 2020
69
7

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
Laura K Ferris, Elyssa Ott, Jingzhi Jiang, H Chih-Ho Hong, Shu Li, Chenglong Han, Wojciech Baran. J Dermatolog Treat 2020
19
26

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
105
7


A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).
Joel M Gelfand, Daniel B Shin, Kristina Callis Duffin, April W Armstrong, Andrew Blauvelt, Stephen K Tyring, Alan Menter, Scott Gottlieb, Benjamin N Lockshin, Eric L Simpson,[...]. J Invest Dermatol 2020
38
13

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
215
5

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
513
5

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
Edmund Lee, William L Trepicchio, Judith L Oestreicher, Debra Pittman, Frank Wang, Francesca Chamian, Madhav Dhodapkar, James G Krueger. J Exp Med 2004
657
5

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
511
5

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan,[...]. N Engl J Med 2015
469
5

IL-12 protects from psoriasiform skin inflammation.
Paulina Kulig, Stephanie Musiol, Sandra Nicole Freiberger, Bettina Schreiner, Gabor Gyülveszi, Giancarlo Russo, Stanislav Pantelyushin, Kenji Kishihara, Francesca Alessandrini, Thomas Kündig,[...]. Nat Commun 2016
104
5

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Richard B Warren, Catherine H Smith, Zenas Z N Yiu, Darren M Ashcroft, Jonathan N W N Barker, A David Burden, Mark Lunt, Kathleen McElhone, Anthony D Ormerod, Caroline M Owen,[...]. J Invest Dermatol 2015
250
5



A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
Kenneth B Gordon, Richard G Langley, Alice B Gottlieb, Kim A Papp, Gerald G Krueger, Bruce E Strober, David A Williams, Yihua Gu, Joaquin M Valdes. J Invest Dermatol 2012
119
5

Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
Lluís Puig, Matthias Augustin, Andrew Blauvelt, Alice B Gottlieb, Ron Vender, Neil J Korman, Diamant Thaçi, Yang Zhao, Isabelle Gilloteau, Bintu Sherif,[...]. J Am Acad Dermatol 2018
19
21

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Kenneth B Gordon, Craig L Leonardi, Mark Lebwohl, Andrew Blauvelt, Gregory S Cameron, Daniel Braun, Janelle Erickson, Michael Heffernan. J Am Acad Dermatol 2014
71
5

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Peter Foley, Kenneth Gordon, Christopher E M Griffiths, Yasmine Wasfi, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, Andrew Blauvelt. JAMA Dermatol 2018
43
9

Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
Bruce Strober, Chitra Karki, Marc Mason, Ning Guo, Stacey H Holmgren, Jeffrey D Greenberg, Mark Lebwohl. J Am Acad Dermatol 2018
37
10

Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.
Mark G Lebwohl, Hervé Bachelez, Jonathan Barker, Giampiero Girolomoni, Arthur Kavanaugh, Richard G Langley, Carle F Paul, Lluís Puig, Kristian Reich, Peter C M van de Kerkhof. J Am Acad Dermatol 2014
304
5

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
K Reich, U Mrowietz, M A Radtke, D Thaci, S J Rustenbach, C Spehr, M Augustin. Arch Dermatol Res 2015
90
5

Pathogenesis of psoriasis and development of treatment.
Eisaku Ogawa, Yuki Sato, Akane Minagawa, Ryuhei Okuyama. J Dermatol 2018
180
5

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
Kristian Reich, James Signorovitch, Karthik Ramakrishnan, Andrew P Yu, Eric Q Wu, Shiraz R Gupta, Yanjun Bao, Parvez M Mulani. J Am Acad Dermatol 2010
26
15

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
M Lebwohl, K Papp, C Han, B Schenkel, N Yeilding, Y Wang, G G Krueger. Br J Dermatol 2010
80
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.